Regen BioPharma, Inc. Updates Report on Success of Its NR2F6 Small Molecule Antagonist Screening Program for Treating Cancer

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has identified a series of small molecule drugs that inhibit NR2F6. Regen’s screening process…